Experimental oral anticoagulation by a directly acting thrombin inhibitor (RGH-2958).

Abstract

D-Phenylalanyl-L-prolyl-L-arginine aldehyde sulfate (RGH-2958), a directly acting synthetic thrombin inhibitor proved to be effective by experimental oral application. The rapid onset of its action has a special importance both from theoretical and practical point of view. Its antiplatelet effect relates to thrombin induced PA and runs parallel with the anticoagulant effect. RGH-2958 significantly reduced the thrombus weight in an experimental thrombosis model in rabbits. In the light of the therapeutic indices of the compound there is a real possibility to open a third way in the prevention and therapy of thrombosis.

• Authors: D Bagdy, E Barabás, Z Fittler, E Orbán, G Rabloczky, S Bajusz, E Széll
• Journal: Folia haematologica (Leipzig, Germany : 1928) (Folia Haematol Int Mag Klin Morphol Blutforsch) Vol. 115 Issue 1-2 Pg. 136-40 ( 1988) ISSN: 0323-4347 [Print] Germany
• PMID: 2459008 (Publication Type: Journal Article)

Chemical References

• Oligopeptides
• H-D-Phe-Pro-arginal
• Thrombin

Topics

• Administration, Oral
• Animals
• Bile (metabolism)
• Blood Coagulation Tests
• Dogs
• Drug Stability
• Duodenum (metabolism)
• Gastric Juice (metabolism)
• Intestinal Absorption
• Oligopeptides (administration & dosage, pharmacokinetics)
• Rabbits
• Thrombin (antagonists & inhibitors)
• Thrombosis (blood)